Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX

JEAN-DAVID FUMET, JULIE VINCENT, LEILA BENGRINE, AUDREY HENNEQUIN, LAURA GRANCONATO, REMI PALMIER and FRANÇOIS GHIRINGHELLI
Anticancer Research July 2020, 40 (7) 4011-4015; DOI: https://doi.org/10.21873/anticanres.14395
JEAN-DAVID FUMET
1Department of Medical Oncology, Center GF Leclerc, Dijon, France
2Research Platform in Biological Oncology, Dijon, France
3GIMI Genetic and Immunology Medical Institute, Dijon, France
4University of Burgundy-Franche Comté, Dijon, France
5UMR INSERM 1231, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JULIE VINCENT
1Department of Medical Oncology, Center GF Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LEILA BENGRINE
1Department of Medical Oncology, Center GF Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AUDREY HENNEQUIN
1Department of Medical Oncology, Center GF Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LAURA GRANCONATO
1Department of Medical Oncology, Center GF Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
REMI PALMIER
1Department of Medical Oncology, Center GF Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANÇOIS GHIRINGHELLI
1Department of Medical Oncology, Center GF Leclerc, Dijon, France
2Research Platform in Biological Oncology, Dijon, France
3GIMI Genetic and Immunology Medical Institute, Dijon, France
4University of Burgundy-Franche Comté, Dijon, France
5UMR INSERM 1231, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fghiringhelli{at}cgfl.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 40 no. 7 4011-4015
DOI 
https://doi.org/10.21873/anticanres.14395
PMID 
32620645

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received May 25, 2020
  • Revision received June 15, 2020
  • Accepted June 16, 2020
  • Published online July 3, 2020.

Copyright & Usage 
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. JEAN-DAVID FUMET1,2,3,4,5,
  2. JULIE VINCENT1,
  3. LEILA BENGRINE1,
  4. AUDREY HENNEQUIN1,
  5. LAURA GRANCONATO1,
  6. REMI PALMIER1 and
  7. FRANÇOIS GHIRINGHELLI1,2,3,4,5⇑
  1. 1Department of Medical Oncology, Center GF Leclerc, Dijon, France
  2. 2Research Platform in Biological Oncology, Dijon, France
  3. 3GIMI Genetic and Immunology Medical Institute, Dijon, France
  4. 4University of Burgundy-Franche Comté, Dijon, France
  5. 5UMR INSERM 1231, Dijon, France
  1. Correspondence to: Professor François Ghiringhelli, MD, Ph.D., Department of Medical Oncology Center Georges François Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France. Tel: +33 380737500, e-mail: fghiringhelli{at}cgfl.fr
View Full Text

Statistics from Altmetric.com

Cited By...

  • 2 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 40, Issue 7
July 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
14 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
JEAN-DAVID FUMET, JULIE VINCENT, LEILA BENGRINE, AUDREY HENNEQUIN, LAURA GRANCONATO, REMI PALMIER, FRANÇOIS GHIRINGHELLI
Anticancer Research Jul 2020, 40 (7) 4011-4015; DOI: 10.21873/anticanres.14395

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
JEAN-DAVID FUMET, JULIE VINCENT, LEILA BENGRINE, AUDREY HENNEQUIN, LAURA GRANCONATO, REMI PALMIER, FRANÇOIS GHIRINGHELLI
Anticancer Research Jul 2020, 40 (7) 4011-4015; DOI: 10.21873/anticanres.14395
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A Landscape of Immunogenomics Assessments for Endemic Burkitt Lymphoma: Relevance to Outcomes
  • Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate Cancer
  • Antiemetic Efficacy of Aprepitant in Cisplatin–Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study
Show more Clinical Studies

Keywords

  • pancreatic cancer
  • chemotherapy
  • Cisplatin
  • Capecitabine
  • gemcitabine
  • docetaxel
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire